JPRN-UMIN000001134已完成2 期
Vinorelbine-carboplatin for patients with stage IIIB, IV non-small cell lung cancer:a phase II study of the Niigata Lung Cancer Treatment Group - Vinorelbine-carboplatin for patients with stage IIIB, IV non-small cell lung cancer:a phase II study of the Niigata Lung Cancer Treatment Group
iigata Lung Cancer Treatment Group0 个研究点目标入组 35 人开始时间: 2008年4月28日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients were excluded if they had any active concomitant malignancies,infections, symptomatic brain metastases, past history of severe allergic reactions to drugs, interstitial pneumonia identified by chest X-ray, or other serious complications, such as uncontrolled angina pectoris, myocardial infarction, heart failure, uncontrolled diabetes mellitus or hypertension, uncontrolled massive pleural effusion or ascites.
研究者
相似试验
Unknown
2 期
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian CancerFallopian Tube CancerOvarian CancerNCT03188159National University Hospital, Singapore36
进行中（未招募）
不适用
Fase II study of carboplatin and vinorelbine in malignant pleural mesothelioma - Fase II MPMPatients with malignant pleural mesothelioma who cannot be operatedEUCTR2005-002223-14-DKRigshospitalet40
尚未招募
2 期
Phase II Trial of Carboplatin plus S-1 for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer complicated by Interstitial Pneumoniaon-small cell lung cancerJPRN-UMIN000011046Department of Respiratory medicine and Rheumatology, Tokushima University Hospital33
进行中（未招募）
1 期
Study to evaluate effectiveness and toxicity of combination vinorelbine, cisplatin and disulfiram and copper for treatment of breast cancer with present circulating tumor cells, who did not respond to previous therapy.MedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)breast cancerEUCTR2019-001957-16-SKárodný onkologický ústav
进行中（未招募）
不适用
VINORELBINE AND CAPECITABINE as first line treatment in advanced breast cancer patients with non measurable lesions for RECIST criteria - VNBCAPmetastatic breast cancerEUCTR2005-005680-29-ITAZIENDA OSPEDALIERA S. LUIGI GONZAGA100